Abivax SA Sponsored ADR $ABVX Stock Holdings Increased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP grew its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 158.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 111,334 shares of the company’s stock after acquiring an additional 68,282 shares during the quarter. Abivax comprises approximately 2.5% of Seven Fleet Capital Management LP’s holdings, making the stock its 7th largest holding. Seven Fleet Capital Management LP owned 0.13% of Abivax worth $14,836,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ABVX. UBS Group AG raised its stake in Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Morgan Stanley grew its stake in shares of Abivax by 114.3% in the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after buying an additional 1,681,277 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new position in shares of Abivax in the 3rd quarter worth $132,800,000. TCG Crossover Management LLC increased its holdings in shares of Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after buying an additional 1,055,000 shares during the last quarter. Finally, Westfield Capital Management Co. LP bought a new stake in shares of Abivax in the 4th quarter worth about $136,199,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Trading Down 1.2%

NASDAQ ABVX opened at $116.52 on Thursday. The stock has a market cap of $10.17 billion, a PE ratio of -22.36 and a beta of 1.03. Abivax SA Sponsored ADR has a 12 month low of $69.81 and a 12 month high of $148.83. The company’s 50-day moving average price is $123.85 and its 200-day moving average price is $119.06.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABVX. Wedbush upped their price objective on Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a research report on Tuesday, June 30th. Citigroup reiterated an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Citizens Jmp reissued a “market outperform” rating and set a $187.00 target price on shares of Abivax in a research report on Wednesday, July 1st. Morgan Stanley reissued an “overweight” rating and set a $180.00 target price on shares of Abivax in a research report on Friday, July 24th. Finally, Truist Financial increased their price target on Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $156.50.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.